P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

Following a protocol amendment to evaluate the efficacy of siltuximab as a first-line treatment of CRS, one patient received siltuximab with full resolution of CRS after two doses without needing additional anti-cytokine-directed therapies...This extended experience demonstrates that CD19.22.BBζ CAR T-cell therapy is safe and clinically active, particularly as a bridge to HSCT. Non-response was confined to patients with non-CNS EMD, highlighting the persistent challenge of effectively targeting EMD and informing the design of future CAR constructs.Trial registration numberNCT03448393.

P3, N=52, Not yet recruiting, R-Pharm International, LLC

In contrast, elevations in general inflammatory markers (white blood cell count, eosinophils, and C-reactive protein) or in lactate dehydrogenase, an indicator of atopic dermatitis, were observed in only a minority of events. These findings suggest that TARC may be a useful biomarker for identifying lenalidomide-induced rash and may aid in optimizing clinical management while maintaining treatment continuity.

P2, N=24, Completed, University of Alabama at Birmingham | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026

This bibliometric analysis highlights the rapidly evolving field of lenalidomide resistance in MM. Future efforts should focus on developing next-generation agents against resistance, designing rational combination therapies targeting key pathways like signal transducer and activator of transcription 3 (STAT3)/ nuclear factor kappa-B (NF-κB), and establishing evidence-based treatment consensus to improve outcomes.

P2/3, N=3110, Recruiting, CSL Behring | N=2310 --> 3110

P1, N=24, Not yet recruiting, CSL Behring

P=N/A, N=911, Completed, Celgene | Active, not recruiting --> Completed

P=N/A, N=100, Completed, Fondazione IRCCS Policlinico San Matteo di Pavia

P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University